<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Tobias</forename><forename type="middle">J</forename><surname>Weismüller</surname></persName>
							<email>tobias.weismueller@gmx.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Gastroenterology, Hepatology and Endocrinology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Palak</forename><forename type="middle">J</forename><surname>Trivedi</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Liver Biomedical Research Centre (BRC)</orgName>
								<orgName type="institution" key="instit1">National Institute for Health Research (NIHR) Birmingham</orgName>
								<orgName type="institution" key="instit2">University of Birmingham</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Liver Unit</orgName>
								<orgName type="institution">University Hospitals Birmingham Queen Elizabeth</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annika</forename><surname>Bergquist</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Center for Digestive Diseases</orgName>
								<orgName type="department" key="dep2">Division of Hepatology</orgName>
								<orgName type="institution">Karolinska University Hospital and Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohamad</forename><surname>Imam</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henrike</forename><surname>Lenzen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Gastroenterology, Hepatology and Endocrinology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cyriel</forename><forename type="middle">Y</forename><surname>Ponsioen</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Academic Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kristian</forename><surname>Holm</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Transplantation Medicine</orgName>
								<orgName type="department" key="dep2">Division of Surgery</orgName>
								<orgName type="laboratory">Norwegian PSC Research Center and Section for Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Inflammatory Diseases and Transplantation</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<settlement>Rikshospitalet, Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><surname>Gotthardt</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Intoxications</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martti</forename><forename type="middle">A</forename><surname>Färkkilä</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Clinic of Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Helsinki University</orgName>
								<orgName type="institution" key="instit2">Helsinki University Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hanns-Ulrich</forename><surname>Marschall</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Molecular and Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Sahlgrenska Academy</orgName>
								<orgName type="institution" key="instit2">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Douglas</forename><surname>Thorburn</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">The Sheila Sherlock Liver Centre</orgName>
								<orgName type="institution" key="instit2">UCL Institute for Liver and Digestive Health</orgName>
								<orgName type="institution" key="instit3">Royal Free Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rinse</forename><forename type="middle">K</forename><surname>Weersma</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">University of Groningen and University Medical Center</orgName>
								<address>
									<settlement>Groningen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johan</forename><surname>Fevery</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Hepatology</orgName>
								<orgName type="institution">University Hospital Gasthuisberg</orgName>
								<address>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tobias</forename><surname>Mueller</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Internal Medicine, Hepatology and Gastroenterology</orgName>
								<orgName type="institution">Charité Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum, 16 Service d&apos;Hépatologie</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="institution">Hôpital Saint Antoine</orgName>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Faculté de Médecine Pierre et Marie Curie</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Assistance Publique-Hôpitaux de Paris</orgName>
								<address>
									<addrLine>17 1st</addrLine>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">University Medical Center Hamburg Eppendorf</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Chazouillères</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kornelius</forename><surname>Schulze</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Konstantinos</forename><forename type="middle">N</forename><surname>Lazaridis</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sven</forename><surname>Almer</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Linköping University</orgName>
								<address>
									<settlement>Linköping</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><forename type="middle">P</forename><surname>Pereira</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Institute for Liver and Digestive Health</orgName>
								<orgName type="institution">University College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cynthia</forename><surname>Levy</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Division of Hepatology</orgName>
								<orgName type="institution">University of Miami</orgName>
								<address>
									<settlement>Miami</settlement>
									<region>Florida</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Mason</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">University of Alberta</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sigrid</forename><surname>Naess</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Transplantation Medicine</orgName>
								<orgName type="department" key="dep2">Division of Surgery</orgName>
								<orgName type="laboratory">Norwegian PSC Research Center and Section for Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Inflammatory Diseases and Transplantation</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<settlement>Rikshospitalet, Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff47">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><forename type="middle">L</forename><surname>Bowlus</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">University of California Davis</orgName>
								<address>
									<settlement>Davis</settlement>
									<region>California</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annarosa</forename><surname>Floreani</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Surgery, Oncology and Gastroenterology</orgName>
								<orgName type="institution">University of Padova</orgName>
								<address>
									<settlement>Padova</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Emina</forename><surname>Halilbasic</surname></persName>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine III</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kidist</forename><forename type="middle">K</forename><surname>Yimam</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Department of Hepatology and Liver Transplantation</orgName>
								<orgName type="institution">California Pacific Medical Center</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<region>California</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Milkiewicz</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department of Clinical and Molecular Biochemistry</orgName>
								<orgName type="institution">Pomeranian Medical University</orgName>
								<address>
									<settlement>Szczecin</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">Department of General, Transplant and Liver Surgery</orgName>
								<orgName type="laboratory">Liver and Internal Medicine Unit</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulrich</forename><surname>Beuers</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Academic Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dep</forename><forename type="middle">K</forename><surname>Huynh</surname></persName>
							<affiliation key="aff28">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Royal Adelaide Hospital</orgName>
								<address>
									<settlement>Adelaide</settlement>
									<region>SA</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Albert</forename><surname>Pares</surname></persName>
							<affiliation key="aff29">
								<orgName type="laboratory">Liver Unit</orgName>
								<orgName type="institution" key="instit1">Hospital Clinic</orgName>
								<orgName type="institution" key="instit2">IDIBAPS</orgName>
								<orgName type="institution" key="instit3">University of Barcelona</orgName>
								<address>
									<region>CIBERehd</region>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><forename type="middle">N</forename><surname>Manser</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Division for Gastroenterology and Hepatology</orgName>
								<orgName type="institution">University Hospital Zurich (USZ)</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">George</forename><forename type="middle">N</forename><surname>Dalekos</surname></persName>
							<affiliation key="aff31">
								<orgName type="department" key="dep1">Department of Medicine and Research Laboratory of Internal Medicine</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Thessaly</orgName>
								<address>
									<settlement>Larissa</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bertus</forename><surname>Eksteen</surname></persName>
							<affiliation key="aff32">
								<orgName type="institution" key="instit1">University of Calgary</orgName>
								<orgName type="institution" key="instit2">Snyder Institute for Chronic Diseases</orgName>
								<address>
									<settlement>Alberta</settlement>
									<region>AB</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pietro</forename><surname>Invernizzi</surname></persName>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">International Center for Digestive Health</orgName>
								<orgName type="department" key="dep2">Department of Medicine and Surgery</orgName>
								<orgName type="institution" key="instit1">Program for Autoimmune Liver Diseases</orgName>
								<orgName type="institution" key="instit2">University of Milan-Bicocca</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><forename type="middle">P</forename><surname>Berg</surname></persName>
							<affiliation key="aff34">
								<orgName type="department">Department of Gastroenterology, Hepatology, and Infectiology</orgName>
								<orgName type="institution" key="instit1">Medical Clinic</orgName>
								<orgName type="institution" key="instit2">University of Tübingen</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">35 Department of Internal Medicine 1</orgName>
								<orgName type="institution">University Hospital of Regensburg</orgName>
								<address>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff36">
								<orgName type="department">36 Department of Internal Medicine 1</orgName>
								<orgName type="institution">Johann Wolfgang Goethe-University Hospital</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabi</forename><forename type="middle">I</forename><surname>Kirchner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Sarrazin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vincent</forename><surname>Zimmer</surname></persName>
							<affiliation key="aff37">
								<orgName type="department">Department of Medicine II</orgName>
								<orgName type="institution">Saarland University Medical Center</orgName>
								<address>
									<settlement>Homburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luca</forename><surname>Fabris</surname></persName>
							<affiliation key="aff38">
								<orgName type="department">Department of Molecular Medicine</orgName>
								<orgName type="institution">University of Padua School of Medicine</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Felix</forename><surname>Braun</surname></persName>
							<affiliation key="aff39">
								<orgName type="department" key="dep1">Department of General</orgName>
								<orgName type="department" key="dep2">Transplantation and Pediatric Surgery</orgName>
								<orgName type="institution">UKSH</orgName>
								<address>
									<addrLine>Campus Kiel</addrLine>
									<settlement>Visceral, Kiel</settlement>
									<region>Thoracic</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Marzioni</surname></persName>
							<affiliation key="aff40">
								<orgName type="department">Clinic of Gastroenterology</orgName>
								<orgName type="institution">Università Politecnica delle Marche</orgName>
								<address>
									<settlement>Ancona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brian</forename><forename type="middle">D</forename><surname>Juran</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karouk</forename><surname>Said</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Center for Digestive Diseases</orgName>
								<orgName type="department" key="dep2">Division of Hepatology</orgName>
								<orgName type="institution">Karolinska University Hospital and Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Rupp</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Intoxications</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kalle</forename><surname>Jokelainen</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Clinic of Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Helsinki University</orgName>
								<orgName type="institution" key="instit2">Helsinki University Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>Benito De Valle</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Molecular and Clinical Medicine</orgName>
								<orgName type="institution" key="instit1">Sahlgrenska Academy</orgName>
								<orgName type="institution" key="instit2">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Francesca</forename><surname>Saffioti</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">The Sheila Sherlock Liver Centre</orgName>
								<orgName type="institution" key="instit2">UCL Institute for Liver and Digestive Health</orgName>
								<orgName type="institution" key="instit3">Royal Free Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Angela</forename><surname>Cheung</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Trauner</surname></persName>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine III</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Schramm</surname></persName>
							<affiliation key="aff41">
								<orgName type="department">Martin Zeitz Center for Rare Diseases</orgName>
								<orgName type="institution">University Medical Center Hamburg Eppendorf</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roger</forename><forename type="middle">W</forename><surname>Chapman</surname></persName>
							<affiliation key="aff42">
								<orgName type="department">Nuffield Department of Clinical Medicine</orgName>
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
							<affiliation key="aff43">
								<orgName type="institution" key="instit1">Translational Gastroenterology Unit</orgName>
								<orgName type="institution" key="instit2">John Radcliffe Hospital</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tom</forename><forename type="middle">H</forename><surname>Karlsen</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Transplantation Medicine</orgName>
								<orgName type="department" key="dep2">Division of Surgery</orgName>
								<orgName type="laboratory">Norwegian PSC Research Center and Section for Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Inflammatory Diseases and Transplantation</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<settlement>Rikshospitalet, Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff47">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erik</forename><surname>Schrumpf</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Department of Transplantation Medicine</orgName>
								<orgName type="department" key="dep2">Division of Surgery</orgName>
								<orgName type="laboratory">Norwegian PSC Research Center and Section for Gastroenterology</orgName>
								<orgName type="institution" key="instit1">Inflammatory Diseases and Transplantation</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<settlement>Rikshospitalet, Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff47">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><forename type="middle">P</forename><surname>Strassburg</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine I</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">P</forename><surname>Manns</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Gastroenterology, Hepatology and Endocrinology</orgName>
								<orgName type="department" key="dep2">Hannover Medical School</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Keith</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Rochester</settlement>
									<region>Minnesota</region>
								</address>
							</affiliation>
							<affiliation key="aff44">
								<orgName type="department" key="dep1">Division of Gastroenterology and Hepatology</orgName>
								<orgName type="department" key="dep2">45 Department of Internal Medicine</orgName>
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<settlement>Phoenix</settlement>
									<region>Arizona</region>
								</address>
							</affiliation>
							<affiliation key="aff45">
								<orgName type="institution">University of North Dakota</orgName>
								<address>
									<addrLine>Grand Forks, North Dakota</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff46">
								<orgName type="department">College of Health Solutions</orgName>
								<orgName type="institution">Arizona State University</orgName>
								<address>
									<settlement>Phoenix</settlement>
									<region>Arizona</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gideon</forename><forename type="middle">M</forename><surname>Hirschfield</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Liver Biomedical Research Centre (BRC)</orgName>
								<orgName type="institution" key="instit1">National Institute for Health Research (NIHR) Birmingham</orgName>
								<orgName type="institution" key="instit2">University of Birmingham</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bettina</forename><forename type="middle">E</forename><surname>Hansen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
							<email>kboberg@ous-hf.no.</email>
						</author>
						<author>
							<affiliation key="aff48">
								<orgName type="department">Department of Gastroenterology and Hepatology</orgName>
								<orgName type="institution">Erasmus University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff49">
								<orgName type="department">Management and Evaluation</orgName>
								<orgName type="institution" key="instit1">Institute of Health Policy</orgName>
								<orgName type="institution" key="instit2">University of Toronto</orgName>
								<address>
									<settlement>Toronto</settlement>
									<region>ON</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff50">
								<orgName type="institution" key="instit1">Toronto Centre for Liver Disease</orgName>
								<orgName type="institution" key="instit2">Toronto General Hospital</orgName>
								<address>
									<settlement>Toronto</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff51">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">University Hospital Bonn</orgName>
								<address>
									<addrLine>Sigmund-Freud-Str. 25</addrLine>
									<postCode>53127</postCode>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff52">
								<orgName type="department" key="dep1">Division of Cancer Medicine</orgName>
								<orgName type="department" key="dep2">Surgery and Transplantation</orgName>
								<orgName type="institution" key="instit1">Norwegian PSC Research Center</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital</orgName>
								<address>
									<postCode>4950, N-0424</postCode>
									<settlement>Rikshospitalet, Nydalen, Oslo</settlement>
									<region>Pb</region>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">2AE0DC0ADE59090432BC08D900D49124</idno>
					<idno type="DOI">10.1053/j.gastro.2017.02.038</idno>
					<note type="submission">Gastroenterology 2017;152:1975-1984 Received April 24, 2016. Accepted February 28, 2017.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:24+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Risk Stratification</term>
					<term>Immune-Mediated Liver Disease</term>
					<term>Autoimmune Liver Disease</term>
					<term>Cholestasis AIH, autoimmune hepatitis</term>
					<term>CCA, cholangiocarcinoma</term>
					<term>CD, Crohn&apos;s disease</term>
					<term>CI, confidence interval</term>
					<term>IBD, inflammatory bowel disease</term>
					<term>IPSCSG, International PSC Study Group</term>
					<term>LT, liver transplantation</term>
					<term>LTD, liver transplantation or death</term>
					<term>PSC, primary sclerosing cholangitis</term>
					<term>sdPSC, small-duct primary sclerosing cholangitis</term>
					<term>UC, ulcerative colitis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>BACKGROUND &amp; AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD).</s><s>We aimed to estimate the risk of disease progression based on distinct clinical phenotypes in a large international cohort of patients with PSC.</s><s>METHODS: We performed a retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centers in Europe, North America, and Australia.</s><s>For each patient, we collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes of IBD and PSC, and date and indication of IBD-related surgeries.</s><s>The primary and secondary endpoints were liver transplantation or death (LTD) and hepatopancreatobiliary malignancy, respectively.</s><s>Cox proportional hazards models were applied to determine the effects of individual covariates on rates of clinical events, with time-to-event analysis ascertained through Kaplan-Meier estimates.</s><s>RESULTS: Of the 7121 patients in the cohort, 2616 met the primary endpoint (median time to event of 14.5 years) and 721 developed hepatopancreatobiliary malignancy.</s><s>The most common malignancy was cholangiocarcinoma (n ¼ 594); patients of advanced age at diagnosis had an increased incidence compared with younger patients (incidence rate: 1.2 per 100 patient-years for patients younger than 20 years old, 6.0 per 100 patient-years for patients 21-30 years old, 9.0 per 100 patient-years for patients 31-40 years old, 14.0 per 100 patient-years for patients 41-50 years old, 15.2 per 100 patient-years for patients 51-60 years old, and 21.0 per 100 patient-years for patients older than 60 years).</s><s>Of all patients with PSC studied, 65.5% were men, 89.8% had classical or large-duct disease, and 70.0%</s><s>developed IBD at some point.</s><s>Assessing the development of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of LTD (unadjusted hazard ratio [HR], 0.62; P &lt; .001</s><s>and HR, 0.90; P ¼ .03,</s><s>respectively) and malignancy (HR, 0.68; P ¼ .008</s><s>and HR, 0.77; P ¼ .004,</s><s>respectively).</s><s>Small-duct PSC was associated with a lower risk of LTD or malignancy compared with classic PSC (HR, 0.30 and HR, 0.15, respectively; both P &lt; .001).</s><s>Female sex was also associated with a lower risk of LTD or malignancy (HR, 0.88; P ¼ .002</s><s>and HR, 0.68; P &lt; .001,</s><s>respectively).</s><s>In multivariable analyses assessing the primary endpoint, small-duct PSC characterized a low-risk phenotype in both sexes (adjusted HR for men, 0.23; P &lt; .001</s><s>and adjusted HR for women, 0.48; P ¼ .003).</s><s>Conversely, patients with ulcerative colitis had an increased risk of liver disease progression compared with patients with Crohn's disease (HR, 1.56; P &lt; .001) or no IBD (HR, 1.15; P ¼ .002).</s><s>CONCLUSIONS: In an analysis of data from individual patients with PSC worldwide, we found significant variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes.</s><s>The survival estimates provided might be used to estimate risk levels for patients with PSC and select patients for clinical trials.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>P rimary sclerosing cholangitis (PSC) is a chronic immune-mediated liver disorder strongly associated with inflammatory bowel disease (IBD). <ref type="bibr">1</ref> Although rare, PSC carries an ongoing and disproportionate clinical need, with clinical outcomes being determined by the development of end-stage biliary cirrhosis and an independent risk of hepatopancreatobiliary (HPB) malignancy.</s><s>]<ref type="bibr">[7]</ref> Accurately reporting the natural history of disease remains a critical challenge not only for clinicians, but also for industry and regulatory agencies who collectively recognize the need for new therapies and equally appreciate the risks and obstacles in demonstrating patient benefit against the background of an orphan disease with a relatively variable, often slow clinical course. <ref type="bibr">9</ref></s><s>Moreover, patients seek reassurance and guidance as to their own prognosis, whereas clinicians wish to confidently recognize those at highest risk of poor outcomes as equally as they strive to reassure individuals with a more favorable prognosis.</s></p><p><s>To expand on single-center and single-country descriptors, the International PSC Study Group (IPSCSG) sponsored a multi-center outcome study to model the natural history of the disease.</s><s>Our primary aim was to evaluate and report the clinical course from a large internationally representative PSC cohort, which included 7121 patients seen at 37 centers across 17 countries, and encompassing &gt;30 years of clinical observation, 1696 LTs, 920 deaths, and 721 incidents of HPB malignancy.</s><s>In so doing, we not only validate the presence of key phenotypic descriptors, but also determine the extent of their interaction and how they may impact the clinical course that patients may experience.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Setting and Design</head><p><s>We collected and analyzed data from well-characterized patients diagnosed with PSC between January 1, 1980 and December 31, 2010, having previously attended or under current clinical follow-up until study completion (June 30, 2014).</s><s>Any individual with an established diagnosis of PSC (including small-duct disease; sdPSC) in accordance with European or American recommendations <ref type="bibr">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr">[12]</ref> was considered eligible for inclusion.</s><s>When biochemical, serologic, and/or histologic features of autoimmune hepatitis (AIH) were evident concurrently or sequentially, <ref type="bibr">13</ref> the diagnosis of a PSC phenotype with AIH features (PSC/AIH variant) was made according to discretion of the participating center.</s><s>IBD phenotypes were determined according to local expertise, <ref type="bibr">[14]</ref><ref type="bibr">[15]</ref><ref type="bibr">[16]</ref> and classified as ulcerative colitis (UC), Crohn's disease (CD), or indeterminate colitis, in keeping with consensus guidelines. <ref type="bibr">17,</ref><ref type="bibr">18</ref></s><s>ta Collection Identification of study participants was performed at a local level, either through a pre-existing and prospectively collected local PSC database, or in a retrospective manner via review of medical records by a named site investigator at a given institution.</s><s>All individual center data were captured onto a multiparametric standardized case record form formulated by the IPSCSG and amalgamated into a common 'master' database for downstream analysis on study completion.</s><s>Individual clinical characteristics pertained to patient sex, clinician-reported age at and date of diagnosis of PSC, sub-phenotype and IBD phenotype, date and indication of IBD-related surgical resections, date of LT, date of death, and date and type of first HPB malignancy.</s><s>Patients with sclerosing cholangitis suspected because of alternate etiologies (eg, IgG4-related disease, acquired immunodeficiency syndromes, confirmed biliary transporter defects) were excluded from the analysis, as were those with inadequate/unknown follow-up duration.</s><s>On completion of data capture, all patient datasets were checked for plausibility and validity, and duplicated patient entries were removed before analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data Interpretation and Analysis</head><p><s>All patients were identified at the time of diagnosis or during subsequent follow-up.</s><s>'Time zero' was set from the point of diagnosis of first PSC phenotype, with the primary endpoint being the incidence rate (and associated risk) of LT, or death in non-transplanted patients.</s><s>Any individual not experiencing a clinical event in this regard was censored at the date of last known follow-up.</s><s>A secondary endpoint of HPB malignancy was also studied, and in this instance the date of first liver transplantation or death (LTD), or last date of event-free follow-up comprised our censor points.</s><s>Diagnosis of HPB malignancy was made according to clinical, radiologic and/or histologic findings as dictated by center-specific protocols.</s></p><p><s>Categorical variables are expressed as numbers (n), with percentages in parenthesis, and continuous data as mean ± standard deviation unless otherwise indicated.</s><s>Statistical comparisons between groups were performed using Pearson's c 2 test.</s><s>Differences in the means and proportions between individual groups of continuous data were assessed using the independent samples t test, following Levene's test for equality of variances. <ref type="bibr">19</ref></s><s>A P value &lt;.05 was considered statistically significant.</s></p><p><s>Univariate and multivariable Cox proportional hazards models were fit to assess the impact of individual covariates on the instantaneous rate of clinical events, with time-to-event analysis ascertained through Kaplan-Meier estimates.</s><s>Given that the development of IBD does not parallel that of PSC, the independent prognostic impact of IBD-phenotype was assessed separately as a time-fixed as well as a time-dependent covariate.</s><s>All individual covariates were assessed for statistically significant interaction terms, including patient demographic features (age and sex) and individual phenotypic descriptors for PSC and IBD subtypes separately.</s><s>All analyses were stratified by geographic region (Australia, North America, Northern Europe, Central Europe, Western Europe, or Southern Europe) and adjusted for year of PSC diagnosis.</s><s>Incidence rates were calculated by the life tables' method.</s><s>Statistical analyses were performed with IBM SPSS Statistics 22.0 (SPSS Inc, Chicago, IL).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethical Approval</head><p><s>This study was conducted in accordance with the protocol and principles of the Declaration of Helsinki.</s><s>The study protocol was reviewed and approved by the local institutional ethical boards of all participating centers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study Population</head><p><s>We accrued clinical data pertaining to 7931 patients (53,983 patient-years); however, those with inadequate follow-up or indeterminate diagnosis of PSC were exempted from further analysis (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>The final patient cohort consisted of 7121 patients, either having PSC in its classical form (89.8%), as small-duct disease (3.6%), or the PSC/AIH variant (6.6%) (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Observing the cohort in its EDITOR'S NOTES</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BACKGROUND AND CONTEXT</head><p><s>Existing data on the natural history and risks for disease progression of PSC are mostly monocentric or regional.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NEW FINDINGS</head><p><s>Incidence of hepatopancreatobiliary (HPB) cancer increased with age at PSC diagnosis.</s><s>Patients with features of autoimmune hepatitis compared with classical PSC showed a similar transplant-free survival but reduced incidence of HPB malignancy.</s><s>PSC patients could be stratified into low-risk, intermediate-risk, and high-risk categories regarding transplant-free survival and HPB cancer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LIMITATIONS</head><p><s>The results are based on a cohort of mostly retrospectively interrogated clinical data from mainly tertiary centers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IMPACT</head><p><s>These results may be used to provide an individualized risk assessment for patient's disease course including HPB malignancy, and to stratify patients for clinical trials.</s></p><p><s>entirety, the majority of patients were men (65.5%), with a mean age at diagnosis of 37 years vs 40 years in women (P &lt; .001).</s><s>Seventy percent of all patients developed concomitant IBD before, at, or following PSC diagnosis, which under most circumstances was morphologically consistent with UC.</s><s>However, the development of UC was less common in women than men (48.1% vs 61.0%, respectively; P &lt; .001),</s><s>and in those with variant PSC subphenotypes relative to classical PSC (frequency of UC in patients with classical PSC: 58.1% vs 33.5% in sdPSC, and vs 47.7% in PSC/AIH; P &lt; .001</s><s>for both pairwise comparisons) (Supplementary Tables <ref type="table" target="#tab_4">1, 2</ref>, and 3).</s></p><p><s>During the defined observation period, 20.2%, 37.0%, 52.3%, and 63.6% of patients underwent LT or died at 5, 10, 15, and 20 years, respectively (Figure <ref type="figure" target="#fig_0">1</ref>), yielding a median transplant-free survival time of 14.5 years (95% confidence interval [CI]: 13.6-15.2</s><s>years; Figure <ref type="figure" target="#fig_1">2A</ref>).</s><s>With regard to our secondary endpoint, 7.1%, 10.9%, 16.0%, and 21.6% of the patient population developed a HPB malignancy at the aforementioned time points (Figure <ref type="figure" target="#fig_1">2B</ref>) (overall n ¼ 721).</s></p><p><s>The majority of HPB malignancy events were cholangiocarcinoma (CCA) (n ¼ 594), and over one third of all malignancies were detected in the first year following PSC diagnosis.</s><s>The incidence of CCA increased with advancing age at PSC diagnosis (Supplementary Figure <ref type="figure" target="#fig_0">1</ref>); whilst hepatocellular carcinoma (n ¼ 59) or gallbladder carcinoma (n ¼ 58) were less frequent.</s><s>Only 10 patients across 7 centers were diagnosed with pancreatic carcinoma.</s><s>HPB malignancy developed most often in association with classical PSC, with only a small number of such events occurring in patients with sdPSC (1 CCA, 2 hepatocellular carcinoma, 1 pancreatic carcinoma) or PSC/AIH variants (12 CCA, 1 gallbladder carcinoma, 1 hepatocellular carcinoma).</s><s>Overall, the development of HPB malignancy at any point during the clinical course was associated with a significantly increased risk of patient mortality (hazard ratio): 15.7; 95% CI: 14.12-17.34;</s><s>P &lt; .001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Stratifiers for LTD and HPB Malignancy</head><p><s>The incidence rates of clinical events according to baseline phenotypic descriptors are provided in Supplementary Tables <ref type="table" target="#tab_6">4 and 5</ref>.</s><s>By univariate analysis, older age at diagnosis was associated with significantly poorer transplant-free survival; whereas female sex, CD (relative to UC), and sdPSC (relative to classical PSC) were identified as being protective (Supplementary Table <ref type="table">6</ref>).</s><s>No significant difference in transplant-free survival was observed between the PSC/AIH variant vs the classical PSC sub-phenotype (Supplementary Figure <ref type="figure" target="#fig_1">2A</ref>), although patients with the former were at a low risk of developing HPB malignancy (Supplementary Figure <ref type="figure" target="#fig_1">2B</ref> and Supplementary Table <ref type="table">6</ref>).</s></p><p><s>The number of patients with IBD increased during our observation period (from 3469 patients at baseline to 4985 patients by the end of our study).</s><s>Given that intestinal disease onset did not necessarily parallel that in the liver, the impact of IBD was subsequently determined as a timedependent covariate.</s><s>In this context, both CD and an  absence of IBD carried stratification properties of a lower risk PSC phenotype; whereas patients developing UC were at highest risk for disease progression, or future development of HPB malignancy (Supplementary Table <ref type="table">6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Sex Modifies the Risk of Liver Disease Progression in Classical PSC</head><p><s>To verify the relative independence of predictive phenotypic features, a comparative multivariable evaluation was performed.</s><s>Through multivariable Cox regression analysis, the prognostic impact of advancing age at diagnosis, as well as protective influences of female sex, having small duct disease, or CD at time of PSC diagnosis, all retained statistical significance in terms of stratifying risk of liver disease progression (Figures <ref type="figure">3 and 4</ref>).</s></p><p><s>Despite both factors being proven as independent riskpredictors, there was a statistically significant interaction (P ¼ .013) between patient sex and PSC sub-phenotypes when evaluating LTD as an endpoint.</s><s>To this effect, patients with sdPSC demonstrated significantly improved transplant-free survival relative to same-sex counterparts with classical PSC and PSC/AIH when matched for their age at PSC diagnosis as well as baseline IBD phenotype (Figure <ref type="figure">4A</ref>).</s><s>These differences were retained when adjusting for the latter as a time-dependent covariate in our multivariable analysis (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Although women more commonly exhibited non-classical PSC   sub-phenotypes than men, statistically significant differences in the risk of LTD between the sexes were retained when restricting our analyses to only those patients with classical PSC (Table <ref type="table" target="#tab_2">2</ref>).</s></p><p><s>Unlike our primary endpoint, no statistically significant interactions were evident between patient sex and PSC sub-phenotypes when determining future HPB risk; wherein being female continued to exert a small, yet independent protective effect (but not an additive one) to that provided by small-duct disease (Figures <ref type="figure">3 and 4</ref>; Table <ref type="table" target="#tab_3">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IBD Phenotype as an Independent Predictor of Clinical Outcome in PSC</head><p><s>CD (at time of PSC diagnosis) relative to UC continued to exert a protective influence with respect to transplant-free survival and the development of HPB malignancy,  Inflammatory bowel disease phenotype is defined as a time-dependent covariate.</s><s>Hazard ratios for PSC sub-phenotypes are presented separately for men and women, and hazard ratios for female versus male are presented separately for each PSC sub-phenotype, given the presence of a significant interaction term between gender and PSC sub-phenotype (P ¼ .005).</s></p><p><s>irrespective of the effect exerted by sex and PSC subphenotype.</s><s>Such impact was not demonstrated in the group without IBD at baseline (Figure <ref type="figure">4</ref>).</s><s>However, when addressing the impact of IBD as a time-dependent covariate, both CD and IBD absence retained independent stratifying properties of a lower-risk PSC population (Tables <ref type="table" target="#tab_4">2 and 3</ref>).</s></p><p><s>No statistically significant interactions existed between the different IBD phenotypes and either PSC sub-phenotype or patient sex.</s><s>Reciprocally, development of UC before, or that which manifest during the clinical course of PSC, significantly increased the risk of LTD by 56% and 15% relative to CD or IBD absence, respectively (Table <ref type="table" target="#tab_2">2</ref>), and of HPB malignancy by approximately 45% and 37%, respectively (Table <ref type="table" target="#tab_3">3</ref>).</s><s>Of all patients with UC, 18.0% (n ¼ 718) underwent colectomy before reaching a primary or secondary endpoint; however, no significant difference in outcome was evident in such individuals relative to those retaining an intact colon (hazard ratio for colectomy in terms of LTD and HPB malignancy: 0.90 [95% CI: 0.78-1.05;</s><s>P ¼ .187]</s><s>and 0.81 [95% CI: 0.61-1.07;</s><s>P ¼ .14],</s><s>respectively).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IBD Phenotype Overrides the Prognostic Impact of Patient Sex</head><p><s>The prognostic impact of IBD phenotype when assessed as a time-dependent variable negated the marginal protective influence of female sex.</s><s>This means that although sex was an independent risk factor of both clinical endpoints statistically, there were no demonstrable differences in either primary or secondary outcomes between men and women when matched for IBD phenotype as a timedependent variable (data not shown).</s><s>Moreover, the lower prevalence of UC in women (Supplementary Table <ref type="table" target="#tab_0">1</ref>) may account partially for differences in liver disease progression between the sexes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>1]<ref type="bibr">[22]</ref> In addition, it is shown that patients with PSC and overlapping AIH features carry a similar risk of liver disease progression to those with a more classical PSC phenotype; although development of HPB malignancy appears to be a rare event in PSC/AIH variants, and also for patients with a young presenting age at PSC diagnosis.</s><s>Furthermore, we were able to address the prognostic impact of IBD development as a time-dependent covariate, recognizing that development of UC is a key stratifier of adverse hepatobiliary consequences in PSC.</s><s>Conversely, IBD absence, and CD in particular, confer prognostic favor independent of the other phenotypic risk factors described.</s></p><p><s>To date, sex-specific variations in clinical phenotype and correlations with patient outcomes in PSC have lacked robust definition.</s><s>Large-scale studies have demonstrated the negative prognostic impact of male sex in patients with related disorders, such as primary biliary cholangitis; specifically an association with treatment non-response and a higher incidence of HPB malignancy. <ref type="bibr">23,</ref><ref type="bibr">24</ref></s><s>As an immune-mediated disease PSC is somewhat atypical, with a propensity for 'most' patients being younger men.</s><s>However, the sex distribution of PSC appears more balanced if cholangiographic screening is applied to all IBD patients, irrespective of biochemical abnormalities or symptomatology. <ref type="bibr">25</ref></s><s>In any event, utilizing the large size of the IPSCSG cohort, men with classical PSC are seen to carry a slight, albeit statistically significant, increased risk of disease progression compared with women of matched phenotype.</s></p><p><s>Our analysis also demonstrates that women with PSC have a much lower prevalence of UC than men.</s><s>This is important because IBD phenotype, particularly when determined as a time-dependent covariate, proves to be an independent risk factor for disease progression and may explain the observed differences in outcome between sexes.</s></p><p><s>Conversely, patients without IBD or those having CD are at a comparatively lower risk of developing adverse events; a finding suggested previously in 2 single-center studies, which we now validate convincingly. <ref type="bibr">14,</ref><ref type="bibr">16</ref></s><s>7]<ref type="bibr">[28]</ref> Notwithstanding efforts to better understand clinical outcomes, our study further supports the need to improve IBD classification in PSC, particularly as the intestinal phenotype is often distinct compared with classical colitis descriptors, <ref type="bibr">15</ref> and more so given that genetic signals in PSC/CD may be disparate to those with PSC/UC. <ref type="bibr">28,</ref><ref type="bibr">29</ref></s><s>f note, our study does not capture details pertaining to the precise distribution of intestinal inflammation; however, prior evidence suggests that CD in PSC is invariably localized to the colon, with isolated ileal disease being a seldom-reported finding. <ref type="bibr">14,</ref><ref type="bibr">16</ref></s><s>o significant outcome differences are apparent between men and women with the variant PSC subphenotypes, and consequently patients with sdPSC (irrespective of gender) experience a relatively sedentary clinical course compared with classical PSC.</s><s>Perhaps more striking, however, is the highly similar transplant-free survival rate seen for patients with classical PSC and those with the PSC/AIH variant.</s><s>Accepting the caveat that PSC/AIH lacks a codified diagnostic criteria, <ref type="bibr">30</ref> these observations challenge the view of PSC/AIH variants imparting a lesser disease burden. <ref type="bibr">31</ref></s><s>Instead, our findings indicate that once overt sclerosing cholangitis has manifest, liver disease may progress at a similar rate irrespective of the initial mode of disease presentation.</s></p><p><s>We also show how development of HPB malignancy (mainly CCA) manifests as a critical event in the clinical course of patients, particularly with advancing age at PSC diagnosis, and associated with significantly diminished patient survival.</s><s>It is plausible that the reason for one third of CCA being identified within the first year following PSC diagnosis is because of a delay in the latter's detection (length-time bias), and not being manifest until CCA is clinically overt.</s><s>This observation highlights the need for improving CCA screening and surveillance, especially in highrisk PSC patients with coexisting UC.</s><s>If better noninvasive surveillance methods for CCA surveillance became available it could support the rationale for systematic screening for PSC in UC patients. <ref type="bibr">25</ref></s><s>On the contrary, as previously described, patients with small duct disease, perhaps indicative of PSC in an earlier form or of shorter duration, carry a lower risk of developing malignancy. <ref type="bibr">2,</ref><ref type="bibr">22</ref></s><s>While this observation was somewhat expected, patients with the PSC/AIH variant are also noted to develop HPB malignancy infrequently.</s><s>This could possibly be a result of a lower UC burden <ref type="bibr">2,</ref><ref type="bibr">20,</ref><ref type="bibr">32,</ref><ref type="bibr">33</ref> that, as our data suggests, is itself an independent hazard for future carcinoma development.</s><s>Furthermore, with only 10 cases during 51,500 patient-years of follow-up we could not validate previous reports <ref type="bibr">37</ref> of a significant increased incidence of pancreatic carcinomas, albeit accepting the clinical challenges that exist in differentiating distal CCAs from primary pancreatic lesions.</s></p><p><s>The natural history of PSC has previously been studied by some of the participating centers comprising the IPSCSG (Supplementary Table <ref type="table">7</ref>), although these cohorts are estimated to constitute, at most, &lt;50% of our current patient population.</s><s>Whilst certain patient characteristics that we describe mirror those in population-based registries, 2 ours is highly representative of a specialist-center PSC experience.</s><s>In light of our prolonged study period, transplant center 'designation' and organ allocation policies have evolved significantly across institutions over time.</s><s>Thus, it is not possible to accurately discriminate clinical outcomes based solely on the division between transplant vs nontransplant centers, as conducted in other settings. <ref type="bibr">2</ref></s><s>Admittedly, we do not present a population-based epidemiologic study, and because more than 95% of included patients derived from centers with contemporary LT activity, a degree of referral bias cannot be discounted.</s><s>This may also explain the relatively low prevalence of sdPSC in our cohort.</s></p><p><s>Given the retrospective nature of our study, the interval frequency of repeated cholangiography varied between centers.</s><s>Therefore, exhaustive surveillance imaging may not have been performed to exclude progression of all small duct cases to classical PSC.</s><s>Similarly, there is no universally accepted guideline for repeated screening colonoscopy in those without IBD, hence we cannot discount that subclinical colitis may have developed in a subset of patients classified as having no IBD.</s><s>]<ref type="bibr">[36]</ref> Our analyses were intentionally restricted to addressing the prognostic impact of well-defined patient phenotypes.</s><s>Consequently, data pertaining to laboratory variables, extent of strictures, intervals of surveillance imaging, or specific pharmacological interventions (eg, ursodeoxycholic acid and/or immunosuppression) fell outside of the current study's remit.</s><s>Further large-scale investigation of therapeutic impact is of critical importance, given the inconsistently reported effects of these agents on disease progression and malignancy risk in PSC. <ref type="bibr">8</ref> Additionally, because a systematic autopsy review was not performed from all mortality cases it is plausible that the incidence of HPB malignancy may in fact be higher than actually reported, <ref type="bibr">37</ref> particularly as CCA cannot always be discriminated from more benign changes in PSC. <ref type="bibr">38</ref></s><s>We are also unable to classify all causes of death in our retrospective patient cohort, although previous studies indicate that mortality in PSC is invariably caused by liver disease or a complication of coexisting IBD. <ref type="bibr">2,</ref><ref type="bibr">39</ref></s><s>A further restriction caused by the retrospective nature and prolonged follow-up period (since 1980) is the fact that serum IgG4 levels were not determined systematically in all patients.</s><s>Therefore, it is not possible to conclusively exclude IgG4-associated cholangiopathy within a subset of our population.</s></p><p><s>The IPSCSG study confirms significant phenotypic diversity across the global PSC patient population.</s><s>The estimates provided for transplant-free survival and the lifetime risk of HPB malignancy would facilitate appropriate patient counselling and also aid in the future evaluation of potential new approaches to malignancy screening.</s><s>In a drive to limit heterogeneity in clinical trials, which currently group together individuals at a high risk of disease progression (classical PSC and UC) together with patients at intermediate risk (CD or IBD-absence) and low risk (sdPSC), our data underpins a collaborative effort to better appraise future therapeutic ventures for this orphan disease.</s><s>As a clear consequence of our findings, future clinical trials may now be able to stratify entry according to a combination of precise phenotypic risk factors, limit the heterogeneity within studied cohorts, and provide a more objective evaluation of therapeutic efficacy in specific patient groups.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>Study cohort: At the time of analysis data were available for 7931 patients.</s><s>However, following exclusion of groups with an alternate diagnose or inadequate follow-up, the final study group consisted of 7121 patients, of which 2616 underwent LT or died, with a total of 721 developing primary HPB malignancy.</s></p></div></figDesc><graphic coords="4,50.46,65.37,239.02,198.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Cumulative incidence of clinical events.</s><s>Kaplan-Meier estimates of (A) LT-free survival rate across the patient population and (B) incidence of all HPB malignancies.</s><s>Notably, 37.8% (n ¼ 272) of all HPB malignancies occurred in the first year of PSC diagnosis, with the vast majority being CCA during this time (incidence rate in the first year after PSC diagnosis: 2.6 cases per 100 patient-years).</s><s>Patients with unknown transplantation, mortality, or malignancy status at the time of study completion were excluded from respective analysis.</s></p></div></figDesc><graphic coords="5,108.11,65.37,377.74,147.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure</head><label></label><figDesc><div><p><s>Figure 3. Impact of patient age and gender on clinical outcome.</s><s>Cox plots with regard to LT or HPB malignancy.</s><s>All data are stratified by geographic region of referring center and year of diagnosis, presented according to patient age at diagnosis and weighted for patient gender, IBD phenotype at baseline, and PSC subphenotype (A and B); or patient gender weighted for patient age at diagnosis, IBD phenotype at baseline, and PSC subphenotype (C and D).</s></p></div></figDesc><graphic coords="5,162.43,473.95,377.74,253.25" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure</head><label></label><figDesc><div><p><s>Figure4.</s><s>Impact of variant PSC sub-phenotypes and IBD phenotypes on clinical outcome.</s><s>Cox plots with regard to LT or HPB malignancy.</s><s>All data are stratified by geographic region of referring center and year of diagnosis, presented according to PSC sub-phenotype weighted for patient age at PSC diagnosis, gender, and IBD phenotype at baseline (A and B); or patient IBD phenotype at baseline weighted for age at PSC diagnosis, gender, and PSC sub-phenotype (C and D).</s></p></div></figDesc><graphic coords="6,49.10,65.37,377.74,234.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Summary of Patient Characteristics</s></p></div></figDesc><table><row><cell>No. of patients</cell><cell>7121</cell></row><row><cell>No. of men</cell><cell>4661 (65.5%)</cell></row><row><cell>Age at diagnosis, y:</cell><cell></cell></row><row><cell>Mean</cell><cell>38.5 (SD: 15.5)</cell></row><row><cell>20</cell><cell>940 (13.2%)</cell></row><row><cell>21-30</cell><cell>1508 (21.2%)</cell></row><row><cell>31-40</cell><cell>1617 (22.7%)</cell></row><row><cell>41-50</cell><cell>1435 (20.2%)</cell></row><row><cell>51-60</cell><cell>953 (13.4%)</cell></row><row><cell>&gt; 60</cell><cell>665 (9.3%)</cell></row><row><cell>unknown</cell><cell>3 (0.04%)</cell></row><row><cell>PSC sub-phenotype:</cell><cell></cell></row><row><cell>classical PSC</cell><cell>6397 (89.8%)</cell></row><row><cell>small duct PSC</cell><cell>254 (3.6%)</cell></row><row><cell>PSC/AIH variant</cell><cell>470 (6.6%)</cell></row><row><cell>Diagnosis year:</cell><cell></cell></row><row><cell>1980-1984</cell><cell>217 (3.0%)</cell></row><row><cell>1985-1989</cell><cell>424 (6.0%)</cell></row><row><cell>1990-1994</cell><cell>773 (10.9%)</cell></row><row><cell>1995-1999</cell><cell>1414 (19.9%)</cell></row><row><cell>2000-2004</cell><cell>1802 (25.3%)</cell></row><row><cell>2005-2010</cell><cell>2491 (35.0%)</cell></row><row><cell>IBD phenotype at baseline:</cell><cell></cell></row><row><cell>Ulcerative colitis</cell><cell>2761 (38.8%)</cell></row><row><cell>Crohn's disease</cell><cell>595 (8.4%)</cell></row><row><cell>Indeterminate colitis</cell><cell>113 (1.6%)</cell></row><row><cell>No IBD</cell><cell>3082 (43.3%)</cell></row><row><cell>Unknown timing</cell><cell>503 (7.1%)</cell></row><row><cell>Unknown IBD status</cell><cell>67 (0.9%)</cell></row><row><cell>IBD phenotype at end of follow-up:</cell><cell></cell></row><row><cell>Ulcerative colitis</cell><cell>3989 (56.0%)</cell></row><row><cell>Crohn's disease</cell><cell>786 (11.0%)</cell></row><row><cell>Indeterminate colitis</cell><cell>210 (2.9%)</cell></row><row><cell>No IBD</cell><cell>2069 (29.1%)</cell></row><row><cell>Unknown IBD status</cell><cell>67 (0.9%)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Risk Stratification of LT/Death by Disease Phenotype</s></p></div></figDesc><table><row><cell cols="2">4. Impact of variant</cell></row><row><cell cols="2">PSC sub-phenotypes and</cell></row><row><cell cols="2">IBD phenotypes on clinical</cell></row><row><cell cols="2">outcome. Cox plots with</cell></row><row><cell cols="2">regard to LT or HPB</cell></row><row><cell cols="2">malignancy. All data are</cell></row><row><cell cols="2">stratified by geographic</cell></row><row><cell cols="2">region of referring center</cell></row><row><cell cols="2">and year of diagnosis,</cell></row><row><cell cols="2">presented according to</cell></row><row><cell>PSC</cell><cell>sub-phenotype</cell></row><row><cell cols="2">weighted for patient age</cell></row><row><cell cols="2">at PSC diagnosis, gender,</cell></row><row><cell cols="2">and IBD phenotype at</cell></row><row><cell cols="2">baseline (A and B); or pa-</cell></row><row><cell cols="2">tient IBD phenotype at</cell></row><row><cell cols="2">baseline weighted for age</cell></row><row><cell cols="2">at PSC diagnosis, gender,</cell></row><row><cell cols="2">and PSC sub-phenotype</cell></row><row><cell>(C and D).</cell><cell></cell></row></table><note><p><s>NOTE.</s><s>All analyses are stratified by geographical region of diagnosis; adjusted for calendar year and age at diagnosis.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Stratification of Hepatopancreatobiliary Malignancy Risk by Disease Phenotype All analyses stratified by geographic region of diagnosis; adjusted for calendar year and age at diagnosis.</s><s>Inflammatory bowel disease phenotype is defined as a time-dependent covariate.</s></p></div></figDesc><table><row><cell>Reference phenotype</cell><cell>Adjusted hazard ratio (95% CI)</cell><cell>P value</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Patient Characteristics by PSC Sub-phenotype a Supplementary Table 3.Patient Characteristics by IBD phenotype (at baseline) a</s></p></div></figDesc><table><row><cell>Women</cell></row><row><cell>(n ¼ 2454) c</cell></row></table><note><p><s>a Data presented as absolute number (%) unless otherwise indicated.bData</s><s>presented only for patients in whom complete respective data are available.c</s><s>Six patients did not have gender data documented.d</s><s>a Data presented as absolute number (%) unless otherwise indicated.</s><s>b Data presented only for patients in whom complete respective data are available.</s><s>a Data presented as absolute number (%) unless otherwise indicated.</s><s>b Data presented only for patients in whom complete respective data are available.</s><s>Supplementary</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Incidence Rates (IR) per 100 Patient-years of Liver transplantation/Death According to Phenotype</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="3">Event: liver transplantation/death</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Male</cell><cell></cell><cell></cell><cell></cell><cell>Female</cell><cell></cell></row><row><cell></cell><cell>UC</cell><cell>CD</cell><cell>IC</cell><cell>No-IBD</cell><cell>UC</cell><cell>CD</cell><cell>IC</cell><cell>No-IBD</cell></row><row><cell>Classical PSC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR</cell><cell>5.5</cell><cell>4.3</cell><cell>4.6</cell><cell>6.3</cell><cell>5.3</cell><cell>3.4</cell><cell>5.5</cell><cell>5.7</cell></row><row><cell>1-year survival</cell><cell>94%</cell><cell>96%</cell><cell>97%</cell><cell>92%</cell><cell>95%</cell><cell>96%</cell><cell>100%</cell><cell>94%</cell></row><row><cell>5-year survival</cell><cell>77%</cell><cell>80%</cell><cell>82%</cell><cell>71%</cell><cell>79%</cell><cell>85%</cell><cell>73%</cell><cell>77%</cell></row><row><cell>10-year survival</cell><cell>59%</cell><cell>67%</cell><cell>73%</cell><cell>55%</cell><cell>61%</cell><cell>72%</cell><cell>62%</cell><cell>60%</cell></row><row><cell>20-year survival</cell><cell>30%</cell><cell>52%</cell><cell>37%</cell><cell>31%</cell><cell>23%</cell><cell>67%</cell><cell>40%</cell><cell>35%</cell></row><row><cell>sdPSC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR</cell><cell>2.5</cell><cell>0.0</cell><cell cols="6">0.0 2.5 100% 2.2 2.7 4.0 0.0 89% 75% 88% -80%</cell></row><row><cell>20-year survival</cell><cell>84%</cell><cell>-</cell><cell>-</cell><cell>82%</cell><cell>56%</cell><cell>-</cell><cell>-</cell><cell>67%</cell></row><row><cell>PSC/AIH-overlap</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR</cell><cell>4.1</cell><cell>4.8</cell><cell>2.1</cell><cell>3.9</cell><cell>5.2</cell><cell>6.6</cell><cell>0.0</cell><cell>5.5</cell></row><row><cell>1-year survival</cell><cell>96%</cell><cell>100%</cell><cell>100%</cell><cell>96%</cell><cell>97%</cell><cell>92%</cell><cell>100%</cell><cell>96%</cell></row><row><cell>5-year survival</cell><cell>86%</cell><cell>92%</cell><cell>83%</cell><cell>78%</cell><cell>79%</cell><cell>61%</cell><cell>-</cell><cell>81%</cell></row><row><cell>10-year survival</cell><cell>73%</cell><cell>69%</cell><cell>83%</cell><cell>68%</cell><cell>69%</cell><cell>41%</cell><cell>-</cell><cell>56%</cell></row><row><cell>20-year survival</cell><cell>45%</cell><cell>69%</cell><cell>-</cell><cell>55%</cell><cell>30%</cell><cell>41%</cell><cell>-</cell><cell>29%</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Incidence Rates (IR) per 100 Patient-years of HPB Malignancy According Phenotype Event: hepatopancreatobiliary (HPB) malignancy a For HPB malignancy, IR are provided for events in the 1 st year only, as well as overall.1984.e6Weismüller</s><s>et alGastroenterology Vol.</s><s>152, No. 8</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Male</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Female</cell><cell></cell></row><row><cell></cell><cell>UC</cell><cell>CD</cell><cell>IC</cell><cell>No-IBD</cell><cell>UC</cell><cell>CD</cell><cell>IC</cell><cell>No-IBD</cell></row><row><cell>Classical PSC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR: 1 st year only</cell><cell>3.1</cell><cell>2.2</cell><cell>3.5</cell><cell>3.8</cell><cell>2.2</cell><cell>2.1</cell><cell>1.9</cell><cell>2.6</cell></row><row><cell>IR: overall</cell><cell>1.6</cell><cell>1.6</cell><cell>1.4</cell><cell>1.7</cell><cell>1.5</cell><cell>0.6</cell><cell>1.5</cell><cell>1.1</cell></row><row><cell>1-year survival</cell><cell>96%</cell><cell>97%</cell><cell>95%</cell><cell>94%</cell><cell>97%</cell><cell>97%</cell><cell>97%</cell><cell>96%</cell></row><row><cell>5-year survival</cell><cell>92%</cell><cell>92%</cell><cell>93%</cell><cell>90%</cell><cell>92%</cell><cell>96%</cell><cell>91%</cell><cell>92%</cell></row><row><cell>10-year survival</cell><cell>86%</cell><cell>87%</cell><cell>93%</cell><cell>86%</cell><cell>86%</cell><cell>95%</cell><cell>78%</cell><cell>90%</cell></row><row><cell>20-year survival</cell><cell>70%</cell><cell>73%</cell><cell>82%</cell><cell>75%</cell><cell>68%</cell><cell>95%</cell><cell>78%</cell><cell>83%</cell></row><row><cell>sdPSC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR: 1 st year only</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell></row><row><cell>IR: overall</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.4</cell><cell cols="2">0.0 0.0 100% -</cell><cell>92%</cell></row><row><cell>20-year survival</cell><cell>100%</cell><cell>-</cell><cell>-</cell><cell>100%</cell><cell>89%</cell><cell>-</cell><cell>-</cell><cell>92%</cell></row><row><cell>PSC/AIH overlap</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IR: 1 st year only</cell><cell>1.5</cell><cell>6.5</cell><cell>0.0</cell><cell>0.7</cell><cell>0.0</cell><cell>0.0</cell><cell>0.0</cell><cell>0.8</cell></row><row><cell>IR: overall</cell><cell>0.7</cell><cell>2.0</cell><cell>0.0</cell><cell>0.2</cell><cell>0.2</cell><cell>1.2</cell><cell>0.0</cell><cell>0.1</cell></row><row><cell>1-year survival</cell><cell>96%</cell><cell>92%</cell><cell>100%</cell><cell>99%</cell><cell>100%</cell><cell>100%</cell><cell>100%</cell><cell>99%</cell></row><row><cell>5-year survival</cell><cell>94%</cell><cell>81%</cell><cell>100%</cell><cell>98%</cell><cell>98%</cell><cell>89%</cell><cell>-</cell><cell>99%</cell></row><row><cell>10-year survival</cell><cell>94%</cell><cell>81%</cell><cell>100%</cell><cell>98%</cell><cell>98%</cell><cell>89%</cell><cell>-</cell><cell>99%</cell></row><row><cell>20-year survival</cell><cell>94%</cell><cell>81%</cell><cell>-</cell><cell>98%</cell><cell>98%</cell><cell>-</cell><cell>-</cell><cell>99%</cell></row></table><note><p><s>a</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">-year survival 96% 100% 100% 99% 100% 100% 100% 95% 5-year survival 96% 100% 100% 89% 100% 88% 100% 86% 10-year survival 96% 100%</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="0">.5 1-year survival 100% 100% 100% 100% 100% 100% 100% 100% 5-year survival 100% 100% 100% 100% 100% 100% 100% 98% 10-year survival 100% 100% 100% 100% 89%</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1984">.e8 Weismüller et al Gastroenterology Vol. 152, No. 8</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org,</s><s>and at http://dx.doi.org/10.1053/</s><s>j.gastro.2017.02.038.</s><s>The following collaborators are acknowledged for their contributions with data acquisition: Benoît Almer, MD (University of Lund).</s></p><p><s>The International PSC Study Group would also like to extend thanks to all patients who contributed to data in the study, as well as the patient support groups (PSC partners and PSC support).</s><s>Sven Almer's current affiliation is the Department of Medicine, Karolinska Institutet, Solna, and Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of interest</head><p><s>The authors disclose no conflicts.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary References</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Hirschfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Karlsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Adams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="1587" to="1599" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Boonstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Weersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Van Erpecum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="2045" to="2055" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Boonstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Beuers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Ponsioen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1181" to="1188" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lindkvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Benito</forename><surname>De Valle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gullberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Björnsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="571" to="577" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Orthotopic liver transplantation for cholestatic diseases</title>
		<author>
			<persName><forename type="first">W</forename><surname>Patkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Skalski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zieniewicz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="605" to="610" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">UK liver transplant audit (NHS Blood and Transplant)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Charman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Copley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tovikkai</surname></persName>
		</author>
		<ptr target="http://www.odt.nhs.uk/pdf/organ_specific_report_liver_2016.pdf.Accessedon" />
		<imprint>
			<date type="published" when="2012-05-07">2012. May 7, 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Liver transplantation in the Nordic countries -An intention to treat and posttransplant analysis from The Nordic Liver Transplant Registry 1982-2013</title>
		<author>
			<persName><forename type="first">B</forename><surname>Fosby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Melum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bjøro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="797" to="808" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vac</forename><surname>Luketic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="808" to="814" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Corpechot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pares</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="644" to="659" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases</title>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="237" to="267" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Diagnosis and management of primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fevery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalloo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="660" to="678" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">ACG clinical guideline: primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Harrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="646" to="659" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Hirschfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="374" to="385" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Halliday</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Djordjevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="174" to="181" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Boonstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Van Erpecum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kmj</forename><surname>Van Nieuwkerk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Bowel Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2270" to="2276" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Patients with large-duct primary sclerosing cholangitis and Crohn&apos;s disease have a better outcome than those with ulcerative colitis, or without IBD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fevery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Steenbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Pelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="612" to="620" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dignass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Eliakim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Magro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="965" to="990" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The second European evidence-based consensus on the diagnosis and management of Crohn&apos;s disease: definitions and diagnosis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Van Assche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dignass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Panes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="7" to="27" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Contributions to probability and statistics: essays in honor of Harold Hotelling</title>
		<author>
			<persName><forename type="first">H</forename><surname>Levene</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1960">1960</date>
			<publisher>Stanford University Press</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1205" to="1211" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Singal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Stanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatol Int</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="808" to="813" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The natural history of small-duct primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Björnsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="975" to="980" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid</title>
		<author>
			<persName><forename type="first">M</forename><surname>Carbone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Mells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pells</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="560" to="569" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>e7</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Lammers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Van Buuren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="321" to="329" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Borthne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="660" to="669" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e4</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ellinghaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Folseraas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Holm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1074" to="1083" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Folseraas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="670" to="675" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">Ji S-G</forename><surname>Juran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Mucha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="269" to="273" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and Crohn&apos;s disease-a comprehensive review</title>
		<author>
			<persName><forename type="first">L</forename><surname>Maroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sfj</forename><surname>Van De Graaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Hohenester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rev Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="182" to="191" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Review article: overlap syndromes and autoimmune liver disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Trivedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Hirschfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="517" to="533" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome</title>
		<author>
			<persName><forename type="first">A</forename><surname>Floreani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Rizzotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ferrara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1516" to="1522" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gotthardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kloeters-Plachky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="313" to="317" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Gulamhusein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Tabibian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="705" to="711" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Disease course and colectomy rate of ulcerative colitis: a follow-up cohort study of a referral center in Tuscany</title>
		<author>
			<persName><forename type="first">N</forename><surname>Manetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bagnoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rogai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Bowel Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1945" to="1953" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Samuel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Ingle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dhillon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Bowel Dis</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1858" to="1866" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Rutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Wilkinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1030" to="1038" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Hepatic and extrahepatic malignancies in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ekbom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Olsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="321" to="327" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Charatcharoenwitthaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Enders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Halling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1106" to="1117" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">High lifetime risk of cancer in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">Mmh</forename><surname>Claessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Vleggaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kmaj</forename><surname>Tytgat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="158" to="164" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rocca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Egeland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1205" to="1211" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lindström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Wikman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="451" to="457" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lindström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hultcrantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="841" to="846" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schaffalitsky De Muckadell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="1464" to="1472" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Vesterhus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Holm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="188" to="197" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Benito De Valle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Björnsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dig Liver Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="903" to="908" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>De Valle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Björnsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lindkvist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="441" to="448" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zenouzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Weismüller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hübener</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1733" to="1738" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study</title>
		<author>
			<persName><forename type="first">Jjw</forename><surname>Tischendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krüger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="107" to="114" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">No evidence that azathioprine increases risk of cholangiocarcinoma in patients with primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zenouzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Weismüller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Jørgensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1806" to="1812" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Jendrek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gotthardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nitzsche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="137" to="144" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study: Malignancies and mortality in PSC</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fevery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Henckaerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Oirbeek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liver Int</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="214" to="222" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Patients with large-duct primary sclerosing cholangitis and Crohn&apos;s disease have a better outcome than those with ulcerative colitis, or without IBD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fevery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Steenbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Van</forename><surname>Pelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="612" to="620" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice</title>
		<author>
			<persName><forename type="first">K</forename><surname>Alswat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Al-Harthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mazrani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="56" to="63" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Garioud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Seksik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chrétien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="842" to="847" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Gotthardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Klöters-Plachky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastrointest Endosc</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="527" to="534" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gotthardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kloeters-Plachky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="313" to="317" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Rupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rössler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Halibasic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aliment Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1292" to="1301" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Rupp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Bode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chahoud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">562</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Evaluation of biliary calprotectin as a biomarker in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stiehl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page">e3510</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group</title>
		<author>
			<persName><forename type="first">L</forename><surname>Okolicsanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fabris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Viaggi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="685" to="691" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Boonstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Weersma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Van Erpecum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="2045" to="2055" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">High lifetime risk of cancer in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">Mmh</forename><surname>Claessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Vleggaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kmaj</forename><surname>Tytgat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="158" to="164" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Ponsioen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sme</forename><surname>Vrouenraets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Prawirodirdjo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="562" to="566" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Four years experience with short term stenting in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Ponsioen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Van Milligen De Wit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="2403" to="2407" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Validation of a cholangiographic prognostic model in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Ponsioen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Reitsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Boberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endoscopy</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="742" to="747" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">U</forename><surname>Broomé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lööf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="610" to="615" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Said</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Broomé</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="88" to="93" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Hepatic and extrahepatic malignancies in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ekbom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Olsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="321" to="327" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a casecontrol study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bergquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="311" to="316" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Imam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Silveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sinakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="182" to="185" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Kowdley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Vac</forename><surname>Luketic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="808" to="814" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Silveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Pardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="1638" to="1645" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Imam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Thackeray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Colorectal Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="198" to="203" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Wiesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Grambsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Dickson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="430" to="436" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Burak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Angulo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Pasha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Egan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Petz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Lindor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="523" to="526" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population</title>
		<author>
			<persName><forename type="first">E</forename><surname>Toy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Balasubramanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Selmi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">83</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis; a 25 year single centre experience</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bannoo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1051" to="1058" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?</title>
		<author>
			<persName><forename type="first">L</forename><surname>Marelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Xirouchakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kalambokis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1224" to="1228" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Natural history and prognostic variables in primary sclerosing cholangitis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Farrant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Hayllar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Wilkinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1710" to="1717" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<monogr>
		<title/>
		<author>
			<persName><surname>Weismüller</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">152</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Sweden</forename><surname>Germany</surname></persName>
		</author>
		<author>
			<persName><surname>Observational</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1989">1989-2008. 1992-2005</date>
			<biblScope unit="page">345</biblScope>
			<pubPlace>Germany) 7,8; Sweden</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Norway</forename><surname>Germany</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">638</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Norway</forename><surname>Germany</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2006">biomarker 2006-2015</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">318</biblScope>
			<pubPlace>Germany; Norway</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Belgium Leuven Observational</title>
		<imprint>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="1975">1975-2012 13</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Canada</forename><surname>Toronto</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<title level="m" type="main">590 c Sweden Multi-regional Observational 1992 28 305 Stockholm Observational 1970-2004 29-31 604 USA Multi-regional Clinical trial</title>
		<imprint>
			<date type="published" when="2008">2008. 2009</date>
			<biblScope unit="page" from="32" to="34" />
		</imprint>
	</monogr>
	<note>Italy Multi-regional Observational 1994 22 117 The Netherlands Multi-regional Observational</note>
</biblStruct>

<biblStruct xml:id="b87">
	<monogr>
		<title level="m" type="main">Multi-regional Observational</title>
		<imprint>
			<date type="published" when="1995">1995-2005</date>
			<biblScope unit="page">33</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title level="m" type="main">174 California Observational 2000-2006 38 169 UK London Observational</title>
		<imprint>
			<date type="published" when="1970">1970-1997 36. 2011</date>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page">128</biblScope>
		</imprint>
	</monogr>
	<note>Minnesota Observational</note>
</biblStruct>

<biblStruct xml:id="b89">
	<monogr>
		<title level="m" type="main">London Observational</title>
		<imprint>
			<date type="published" when="1990">1990-2009</date>
			<biblScope unit="page">40</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main">London Observational</title>
		<imprint>
			<date type="published" when="1972">1972-1989</date>
			<biblScope unit="page">41</biblScope>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
